Blockade of programmed cell death ligand-1 with durvalumab has shown efficacy and safety in large, international studies of patients with advanced solid tumors. A phase 1, non-randomized, open-label multicenter study was initiated to evaluate durvalumab in a Japanese population. The first part of this study used a standard 3 + 3 dose-escalation design to determine the optimal dosing schedule of durvalumab. Primary objective was evaluation of safety and tolerability of durvalumab monotherapy. Secondary objectives were to evaluate maximum tolerated dose (MTD), immunogenicity, pharmacokinetics, and efficacy. Twenty-two patients (median age, 61.5 years; range, 41-76; 64% male) received durvalumab at doses of 1, 3, or 10 mg/kg every 2 weeks (q2w), 15 mg/kg q3w, or 20 mg/kg q4w. Twenty patients discontinued before completing 12 months of treatment as a result of progressive disease and two due to adverse events (AE). The most common treatment-related AE (trAE) were rash (18%) and pruritus (14%); two patients had grade ≥3 trAE including one patient each with hyponatremia and hypothyroidism.
| INTRODUC TI ON
The programmed cell death-1 receptor and ligand (PD-L1) pathway has recently emerged as a prominent therapeutic target for preventing tumor escape from immune surveillance in cancer. 1, 2 Physiologically, PD-1/PD-L1 expression constitutes an important checkpoint for immune tolerance. However, in the tumor microenvironment, this pathway allows TC to circumvent host immunity, leading to tumor progression and survival through effects on T cells that include dysfunction, exhaustion, neutralization, and immunosuppression. 3 The clinical relevance of the PD-1/PD-L1 pathway has been demonstrated in a range of solid tumors following the therapeutic success of PD-1 and PD-L1 checkpoint blockade, with beneficial outcomes associated with mutational burden of TC, presence of tumorinfiltrating immune cells, and PD-L1 expression. 4 Overexpression of PD-L1, in particular, has been associated with poor prognosis in different tumor types and thus represents a rational target for cancer immunotherapy. [5] [6] [7] In addition to its membrane expression, PD-L1 has a soluble form (sPD-L1) that has been shown to have PD-1-binding capacity, with its concentration in plasma correlating with tumor aggressiveness and outcome in different tumor types. [8] [9] [10] [11] A recent meta-analysis of patients with solid tumors confirmed that high circulating concentrations of sPD-L1 predicted shorter OS, indicating that a high sPD-L1
level may serve as a prognostic biomarker. 12 Anti-PD-L1 blockade with durvalumab, a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD-80, has demonstrated efficacy and safety in large, international studies of patients with advanced/metastatic NSCLC and UC. [13] [14] [15] [16] Patients with locally advanced, unresectable NSCLC (stage 3) who were treated with durvalumab after platinum-based chemoradiotherapy in a phase 3 trial experienced significantly longer OS, PFS, and time to distant metastasis compared with placebo. 13, 16 Among 191 patients with locally advanced or metastatic UC, ORR with single-agent durvalumab (10 mg/kg q2w) was 17.8% and median PFS and OS were 1.5 and 18.2 months, respectively. Grade 3/4 trAE occurred in 13 patients (6.8%); grade 3/4 imAE occurred in four patients (2.1%); and trAE led to discontinuation of three patients (1.6%), two of whom had imAE that led to death (autoimmune hepatitis and pneumonitis). 14, 15 This encouraging antitumor activity and manageable safety profile resulted in the approval of durvalumab in the USA for treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy as well as for patients with unresectable stage 3 NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy; [13] [14] [15] [16] durvalumab has also been approved in several other countries worldwide, including Japan.
The first portion of the phase 1 Japan 02 Study is a doseescalation phase designed to assess the safety, tolerability, and PK of escalating doses and different dosing schedules of durvalumab as monotherapy in Japanese patients with advanced solid tumors. 
| Patients
Males or females aged 20 years or older were eligible for enrollment. In the dose-escalation phase, patients with advanced solid tumors refractory to standard treatment, intolerant of standard treatment, or for whom no standard therapy exists, were included.
In addition, eligible patients had to have at least one measur- 
| Treatment schedule
Dose-limiting toxicity was assessed during the DLT evaluation period of 4 weeks in groups 1, 2, 3, and 5, and 3 weeks in group 4 after first dosing with durvalumab. Group 1 received durvalumab 1.0 mg/kg by i.v. infusion q2w. If no DLT was observed in the first three evaluable patients, then dose escalation was planned to occur at the next dose level; if one patient experienced a DLT in a group of three evaluable patients, the group was expanded to include three additional evaluable patients. If only one DLT occurred in a group of six evaluable patients for group 1, then dose escalation was planned with enrollment of patients to group 2, who received 3.0 mg/kg q2w and subsequently to group 3, who received 10 mg/kg q2w ( Figure   S1 ). If two or more patients experienced a DLT in a group of up to six patients, dose escalation was stopped irrespective of the number of patients enrolled, with a lower intermediary dose considered in order to define the MTD. After completion of the durvalumab q2w dose escalation, separate q3w (group 4) and q4w dose (group 5) escalations were started at the equivalent dosing rate (average mg/kg per wk) to the optimal biological dose, or highest dose tested if an optimal biological dose was not identified. If an MTD was reached prior to completing the q2w dose escalation, the q3w and q4w starting doses were to be equivalent to 1 dose level below the q2w MTD.
| Study procedures and assessments
Patients underwent initial screening within 28 days prior to the first dose of study drug. A 3-hour post-infusion observation was carried out on the day of first dosing with durvalumab. For subsequent doses, the 3-hour post-infusion period was required only for patients who experienced an infusion-related reaction. Patients additionally underwent safety, laboratory, and efficacy evaluations during treatment, at the end of treatment, and during the follow-up period.
Adverse events were based upon investigator assessment; AE, SAE, and concomitant treatment assessments were conducted post-dosing. AESI were determined using clinical concepts and se- Patients who discontinued durvalumab during initial treatment or retreatment entered a 3-month follow up for evaluation of safety and survival.
Assessment of sPD-L1 concentration was made from blood samples taken at screening, dose 1, dose 2, and on other dose days up to week 7. The number of observations above the lower limit of quantification (LLOQ) was recorded together with the median (minimum, maximum) titers.
Programmed cell death ligand-1 status was determined from archival or fresh tumor samples taken at screening using the VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems, Inc., Tucson, AZ, USA), with PD-L1-low/negative expression (TC <25%) defined as less than 25% TC expressing PD-L1 at any staining intensity above background. Serum PK parameters were assessed for durvalumab and summarized for each dose group. Parameters of interest were drug exposure determined as AUC 0-t , and C max , C max /dose and T max .
ADA titers were determined for durvalumab, with maximum titer summarized by median (minimum, maximum) for each dose group.
| Statistical analyses
Analyses were carried out by dose level using descriptive sta- 
| RE SULTS

| Patients
Twenty-five patients were enrolled into the study of which three patients failed to meet eligibility criteria during the screening period after signing informed consent and were not assigned to treatment. All 22 patients were included in the SAS, RES, PK, and ADA analysis sets. Two patients were excluded from the DLT evaluable set as they did not meet the protocol-defined AE follow-up duration; one patient receiving 1.0 mg/kg q2w discontinued before the second durvalumab dose as a result of PD and one patient receiving 3.0 mg/kg q2w did not receive a second durvalumab dose.
Baseline demographics are summarized in 
| Safety
Treatment-related adverse events that were most frequently reported in the entire dose-escalation population were rash (4 [18%] patients), pruritus, constipation, nausea, stomatitis, and pyrexia 
| Pharmacokinetics and immunogenicity
Durvalumab showed dose-proportional PK across the 1. (Table 3) . T max was similar across the dose groups (Table 3) .
Antidrug antibody response to durvalumab including immunogenicity titers of ADA-positive samples was determined for each dose group (Table S1) 
Tumor type, n (%)
Gastric/ gastroesophageal 0 1 (25) 1 (25) 1 (17) 1 (25) 4 ( (14) q2w, every 2 weeks; q3w, every 3 weeks; q4w, every 4 weeks; trAE, treatment-related adverse event. a Safety analysis set.
| Efficacy
Objective response rate was 4.5%. One patient in the 10 mg/kg q2w dose group had a PR, with a duration of response of 4.2 months; this patient had NSCLC.
Disease control rate at 6, 12, and 24 weeks for all patients in the study was 64%, 36%, and 23%, respectively, and is summarized for each dose group in Table S2 . This included two of four patients each in the 
| D ISCUSS I ON
Overall, durvalumab was generally well tolerated without DLT in these patients with a range of solid tumor types, including gastric/ gastroesophageal cancer, NSCLC, and other advanced solid tumors.
Number of patients with trAE was similar across the dose groups, and consistent with previous reports of PD-1/PD-L1 blockade in general [17] [18] [19] [20] [21] and durvalumab specifically; 13, 15, 22, 23 As there was no dose-response between PD-L1/PD-1 axis blockade and antitumor effects, and as 10 and 20 mg/kg were the highest doses evaluated for the q2w and q4w regimens, respectively, these doses were selected for study expansion. Furthermore, as toxicity of durvalumab was not a function of dose or exposure, higher doses were not assessed.
A low incidence of positive ADA to durvalumab was observed.
ADA did not appear to impact the PK of durvalumab and efficacy.
This has been seen in other studies with durvalumab, given in combination with tremelimumab; low levels of ADA were observed following treatment. 22 Also, in these studies, no association between ADA and tolerability or antitumor activity was determined. Although all patients enrolled in this portion of the study did not show high expression levels for PD-L1 (all had 25% or fewer TC that expressed PD-L1), preliminary antitumor activity was observed, with one PR in a patient with NSCLC, and 36% and 23% of patients overall achieving disease control at 12 and 24 weeks, respectively. Pharmacokinetic evaluation showed a dose-proportional relationship for C max over the 1.0-20 mg/kg dose range and for AUC 0-t over the 1-10 mg/kg q2w dose range. As in a previous study, 24 no relationship was observed between drug exposure and safety, with higher drug exposure not associated with an increased risk of AE. Absence of DLT and a MTD of durvalumab is also consistent with other reports. 25 In a population PK analysis, the PK characteristics of durvalumab were best described using a two-compartment model with nonlinear elimination kinetics at doses <3 mg/kg and linear kinetics at higher doses. 26 The pharmacodynamic effects of durvalumab were also evaluated using sPD-L1 plasma concentration as a potential predictive 
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